The University of Southampton
University of Southampton Institutional Repository

Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups

Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups
Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups
- Novel long-acting coronavirus prophylactic monoclonal antibody therapies have been shown to be effective in preventing COVID-19 in immunocompromised individuals who are at increased risk from SARS-CoV-2.
- Prophylactic antibody therapies should be made available in a timely manner to give an antibody immunity boost to vulnerable patients.
- Real world evaluations should be co-implemented to provide confidence of ongoing effectiveness.
- Successful delivery of a coronavirus prophylactic antibody therapy programme would deliver significant benefits to healthcare systems, communities and immunocompromised individuals.
Lim, Sean
fe9a89e4-c852-4e9d-a966-91313f38aa18
Orchard, Kim
794654ab-d6cc-488a-ac11-c9217433c7a2
Fernandes, Peter
a0ee518d-212a-438f-954a-0e7f0ae05234
Lim, Sean
fe9a89e4-c852-4e9d-a966-91313f38aa18
Orchard, Kim
794654ab-d6cc-488a-ac11-c9217433c7a2
Fernandes, Peter
a0ee518d-212a-438f-954a-0e7f0ae05234

Lim, Sean, Orchard, Kim and Fernandes, Peter (2022) Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups.

Record type: Other

Abstract

- Novel long-acting coronavirus prophylactic monoclonal antibody therapies have been shown to be effective in preventing COVID-19 in immunocompromised individuals who are at increased risk from SARS-CoV-2.
- Prophylactic antibody therapies should be made available in a timely manner to give an antibody immunity boost to vulnerable patients.
- Real world evaluations should be co-implemented to provide confidence of ongoing effectiveness.
- Successful delivery of a coronavirus prophylactic antibody therapy programme would deliver significant benefits to healthcare systems, communities and immunocompromised individuals.

This record has no associated files available for download.

More information

Published date: 31 July 2022

Identifiers

Local EPrints ID: 469272
URI: http://eprints.soton.ac.uk/id/eprint/469272
PURE UUID: bda032a8-2fe0-4060-aed9-8edabd541b3b
ORCID for Kim Orchard: ORCID iD orcid.org/0000-0003-2276-3925

Catalogue record

Date deposited: 12 Sep 2022 16:41
Last modified: 04 Aug 2023 01:36

Export record

Contributors

Author: Sean Lim
Author: Kim Orchard ORCID iD
Author: Peter Fernandes

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×